Elo Mutual Pension Insurance Co Makes New Investment in Insmed, Inc. $INSM

Elo Mutual Pension Insurance Co acquired a new stake in shares of Insmed, Inc. (NASDAQ:INSM) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 15,086 shares of the biopharmaceutical company’s stock, valued at approximately $2,173,000.

Several other large investors have also made changes to their positions in the company. Atria Investments Inc lifted its holdings in Insmed by 75.3% during the 2nd quarter. Atria Investments Inc now owns 16,810 shares of the biopharmaceutical company’s stock valued at $1,692,000 after purchasing an additional 7,219 shares during the last quarter. Amalgamated Bank raised its stake in shares of Insmed by 117.3% in the second quarter. Amalgamated Bank now owns 12,973 shares of the biopharmaceutical company’s stock valued at $1,306,000 after acquiring an additional 7,003 shares during the last quarter. Bryce Point Capital LLC bought a new position in shares of Insmed in the second quarter valued at approximately $583,000. Fourth Dimension Wealth LLC boosted its holdings in shares of Insmed by 43.8% in the 2nd quarter. Fourth Dimension Wealth LLC now owns 2,332 shares of the biopharmaceutical company’s stock worth $235,000 after acquiring an additional 710 shares in the last quarter. Finally, First Horizon Advisors Inc. grew its position in Insmed by 24.8% during the 2nd quarter. First Horizon Advisors Inc. now owns 936 shares of the biopharmaceutical company’s stock worth $94,000 after acquiring an additional 186 shares during the last quarter.

Insmed Price Performance

Insmed stock opened at $149.88 on Thursday. The business’s 50-day simple moving average is $159.98 and its 200 day simple moving average is $165.37. The company has a quick ratio of 3.54, a current ratio of 3.83 and a debt-to-equity ratio of 0.76. The stock has a market cap of $32.31 billion, a price-to-earnings ratio of -23.38 and a beta of 1.13. Insmed, Inc. has a 12-month low of $60.40 and a 12-month high of $212.75.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.47). The business had revenue of $263.84 million for the quarter, compared to analyst estimates of $263.97 million. Insmed had a negative net margin of 210.54% and a negative return on equity of 168.36%. The business’s revenue for the quarter was up 152.6% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.32) earnings per share. As a group, research analysts anticipate that Insmed, Inc. will post -4.56 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have issued reports on INSM shares. Cantor Fitzgerald lifted their price objective on Insmed from $216.00 to $230.00 and gave the company an “overweight” rating in a research report on Tuesday, December 16th. Mizuho lowered their target price on Insmed from $211.00 to $204.00 and set an “outperform” rating for the company in a research note on Tuesday, February 24th. Truist Financial set a $205.00 price target on Insmed in a report on Monday, January 12th. Roth Mkm raised shares of Insmed to a “strong-buy” rating in a report on Friday, January 23rd. Finally, UBS Group lowered their price objective on shares of Insmed from $223.00 to $215.00 and set a “buy” rating for the company in a research report on Tuesday, January 6th. Three analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $207.52.

Insider Activity at Insmed

In other Insmed news, insider Orlov S. Nicole Schaeffer sold 87,290 shares of the firm’s stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $175.20, for a total value of $15,293,208.00. Following the transaction, the insider directly owned 41,754 shares of the company’s stock, valued at approximately $7,315,300.80. This trade represents a 67.64% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO William Lewis sold 19,215 shares of the company’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $169.00, for a total transaction of $3,247,335.00. Following the sale, the chief executive officer owned 306,891 shares of the company’s stock, valued at $51,864,579. The trade was a 5.89% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 178,952 shares of company stock worth $30,222,170 over the last 90 days. 3.00% of the stock is currently owned by company insiders.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.